Host factors mediating HIV-1 replication

Brian M. Friedrich, Natallia Dziuba, Guangyu Li, Mark Endsley, James L. Murray, Monique Ferguson

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Human immunodeficiency virus type 1(HIV-1) infection is the leading cause of death worldwide in adults attributable to infectious diseases. Although the majority of infections are in sub-Saharan Africa and Southeast Asia, HIV-1 is also a major health concern in most countries throughout the globe. While current antiretroviral treatments are generally effective, particularly in combination therapy, limitations exist due to drug resistance occurring among the drug classes. Traditionally, HIV-1 drugs have targeted viral proteins, which are mutable targets. As cellular genes mutate relatively infrequently, host proteins may prove to be more durable targets than viral proteins. HIV-1 replication is dependent upon cellular proteins that perform essential roles during the viral life cycle. Maraviroc is the first FDA-approved antiretroviral drug to target a cellular factor, HIV-1 coreceptor CCR5, and serves to intercept viral-host protein-protein interactions mediating entry. Recent large-scale siRNA and shRNA screens have revealed over 1000 candidate host factors that potentially support HIV-1 replication, and have implicated new pathways in the viral life cycle. These host proteins and cellular pathways may represent important targets for future therapeutic discoveries. This review discusses critical cellular factors that facilitate the successive steps in HIV-1 replication.

Original languageEnglish (US)
Pages (from-to)101-114
Number of pages14
JournalVirus Research
Volume161
Issue number2
DOIs
StatePublished - Nov 2011

Fingerprint

Virus Replication
HIV-1
Viral Proteins
Life Cycle Stages
Small Interfering RNA
Proteins
Pharmaceutical Preparations
Southeastern Asia
Africa South of the Sahara
Virus Diseases
Drug Resistance
Communicable Diseases
Cause of Death
Health
Therapeutics
Infection
Genes

Keywords

  • Cellular factors
  • HIV-1 replication
  • Virus-host interactions

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases
  • Cancer Research

Cite this

Host factors mediating HIV-1 replication. / Friedrich, Brian M.; Dziuba, Natallia; Li, Guangyu; Endsley, Mark; Murray, James L.; Ferguson, Monique.

In: Virus Research, Vol. 161, No. 2, 11.2011, p. 101-114.

Research output: Contribution to journalArticle

Friedrich, BM, Dziuba, N, Li, G, Endsley, M, Murray, JL & Ferguson, M 2011, 'Host factors mediating HIV-1 replication', Virus Research, vol. 161, no. 2, pp. 101-114. https://doi.org/10.1016/j.virusres.2011.08.001
Friedrich, Brian M. ; Dziuba, Natallia ; Li, Guangyu ; Endsley, Mark ; Murray, James L. ; Ferguson, Monique. / Host factors mediating HIV-1 replication. In: Virus Research. 2011 ; Vol. 161, No. 2. pp. 101-114.
@article{6f2b1da44716445ea943f80cabe17e3a,
title = "Host factors mediating HIV-1 replication",
abstract = "Human immunodeficiency virus type 1(HIV-1) infection is the leading cause of death worldwide in adults attributable to infectious diseases. Although the majority of infections are in sub-Saharan Africa and Southeast Asia, HIV-1 is also a major health concern in most countries throughout the globe. While current antiretroviral treatments are generally effective, particularly in combination therapy, limitations exist due to drug resistance occurring among the drug classes. Traditionally, HIV-1 drugs have targeted viral proteins, which are mutable targets. As cellular genes mutate relatively infrequently, host proteins may prove to be more durable targets than viral proteins. HIV-1 replication is dependent upon cellular proteins that perform essential roles during the viral life cycle. Maraviroc is the first FDA-approved antiretroviral drug to target a cellular factor, HIV-1 coreceptor CCR5, and serves to intercept viral-host protein-protein interactions mediating entry. Recent large-scale siRNA and shRNA screens have revealed over 1000 candidate host factors that potentially support HIV-1 replication, and have implicated new pathways in the viral life cycle. These host proteins and cellular pathways may represent important targets for future therapeutic discoveries. This review discusses critical cellular factors that facilitate the successive steps in HIV-1 replication.",
keywords = "Cellular factors, HIV-1 replication, Virus-host interactions",
author = "Friedrich, {Brian M.} and Natallia Dziuba and Guangyu Li and Mark Endsley and Murray, {James L.} and Monique Ferguson",
year = "2011",
month = "11",
doi = "10.1016/j.virusres.2011.08.001",
language = "English (US)",
volume = "161",
pages = "101--114",
journal = "Virus Research",
issn = "0168-1702",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Host factors mediating HIV-1 replication

AU - Friedrich, Brian M.

AU - Dziuba, Natallia

AU - Li, Guangyu

AU - Endsley, Mark

AU - Murray, James L.

AU - Ferguson, Monique

PY - 2011/11

Y1 - 2011/11

N2 - Human immunodeficiency virus type 1(HIV-1) infection is the leading cause of death worldwide in adults attributable to infectious diseases. Although the majority of infections are in sub-Saharan Africa and Southeast Asia, HIV-1 is also a major health concern in most countries throughout the globe. While current antiretroviral treatments are generally effective, particularly in combination therapy, limitations exist due to drug resistance occurring among the drug classes. Traditionally, HIV-1 drugs have targeted viral proteins, which are mutable targets. As cellular genes mutate relatively infrequently, host proteins may prove to be more durable targets than viral proteins. HIV-1 replication is dependent upon cellular proteins that perform essential roles during the viral life cycle. Maraviroc is the first FDA-approved antiretroviral drug to target a cellular factor, HIV-1 coreceptor CCR5, and serves to intercept viral-host protein-protein interactions mediating entry. Recent large-scale siRNA and shRNA screens have revealed over 1000 candidate host factors that potentially support HIV-1 replication, and have implicated new pathways in the viral life cycle. These host proteins and cellular pathways may represent important targets for future therapeutic discoveries. This review discusses critical cellular factors that facilitate the successive steps in HIV-1 replication.

AB - Human immunodeficiency virus type 1(HIV-1) infection is the leading cause of death worldwide in adults attributable to infectious diseases. Although the majority of infections are in sub-Saharan Africa and Southeast Asia, HIV-1 is also a major health concern in most countries throughout the globe. While current antiretroviral treatments are generally effective, particularly in combination therapy, limitations exist due to drug resistance occurring among the drug classes. Traditionally, HIV-1 drugs have targeted viral proteins, which are mutable targets. As cellular genes mutate relatively infrequently, host proteins may prove to be more durable targets than viral proteins. HIV-1 replication is dependent upon cellular proteins that perform essential roles during the viral life cycle. Maraviroc is the first FDA-approved antiretroviral drug to target a cellular factor, HIV-1 coreceptor CCR5, and serves to intercept viral-host protein-protein interactions mediating entry. Recent large-scale siRNA and shRNA screens have revealed over 1000 candidate host factors that potentially support HIV-1 replication, and have implicated new pathways in the viral life cycle. These host proteins and cellular pathways may represent important targets for future therapeutic discoveries. This review discusses critical cellular factors that facilitate the successive steps in HIV-1 replication.

KW - Cellular factors

KW - HIV-1 replication

KW - Virus-host interactions

UR - http://www.scopus.com/inward/record.url?scp=80053132394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053132394&partnerID=8YFLogxK

U2 - 10.1016/j.virusres.2011.08.001

DO - 10.1016/j.virusres.2011.08.001

M3 - Article

VL - 161

SP - 101

EP - 114

JO - Virus Research

JF - Virus Research

SN - 0168-1702

IS - 2

ER -